Maintenance Phase - Bonus: Mike's New Podcast!

Oct 10, 2023

Ozempic

Ozempic is being hailed as “the end of the Obesity Epidemic.” This week, Mike and Aubrey dig through the sensational claims. But will they make it past the caveats? *Links:* * How a Canadian scientist and a venomous lizard helped pave the way for Ozempic * The Discovery and Development of Liraglutide and Semaglutide * Ozempic and Wegovy maker courts prominent Black leaders to get Medicare's favor * Insurers clamping down on doctors who prescribe Ozempic for weight loss * Ozempic prescriptions can be easy to get online. Its popularity for weight loss is hurting those who need it most * Glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: real-world evidence from a Mediterranean area * Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity * Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK * Safety of Semaglutide * Semaglutide for the treatment of overweight and obesity: A review * Once-Weekly Semaglutide in Adolescents with Obesity * Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5 * Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases * Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States * Medications and conditions associated with weight loss in patients prescribed semaglutide based on real-world data Thanks to Doctor Dreamchip for our lovely theme song!Support the show

58 min